drug_type
RELEVANT_DRUG
intervention_type
cellular therapy
drug_description
Engineered autologous T cells expressing a BCMA-directed chimeric antigen receptor to mediate cytotoxicity against malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a BCMA-directed chimeric antigen receptor; engagement of BCMA (TNFRSF17) on malignant plasma cells triggers CAR signaling (CD3ΞΆ with co-stimulatory domains), activating T-cell proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of myeloma cells.
drug_name
Anti-BCMA CAR-T cells (autologous)
nct_id_drug_ref
NCT05850286